CureVac (CVAC) Osake Kurssi
CureVac Kurssi
Viimeisten 6 vuoden aikana CureVacn liikevaihto kasvoi 86,1 % vuodessa ja ylsi 535,18 M EUR:een. CureVacn nettomarginaali 30,3 % on noussut verrattuna −264,0 %:iin muutama vuosi sitten. CureVacn 12 kuukauden konsensustavoitehinta on 4,99 EUR, noin yli kurssia 22,4 %. 11 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Osta.
CureVac osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
CureVac liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset CureVac -osakkeesta
Some of the main competitors of CureVac NV in the market are Moderna Inc., BioNTech SE, and Pfizer Inc. These companies also specialize in the development of mRNA-based therapeutics and vaccines. However, CureVac NV differentiates itself through its proprietary RNAoptimizer platform, which enables efficient, scalable, and cost-effective mRNA production. With its innovative technology and a strong pipeline of candidates, CureVac NV aims to create a significant presence in the market.
The business model of CureVac NV focuses on the development of transformative messenger RNA (mRNA) therapeutics and vaccines. By leveraging its proprietary mRNA platform, CureVac aims to address various diseases and medical conditions across multiple therapeutic areas, including infectious diseases, oncology, and rare diseases. Their mRNA technology allows for the production of vaccine candidates and therapeutic proteins, which can be customized to target specific diseases. This innovative approach offers potential advantages such as rapid development, scalability, and adaptability. As a leading biopharmaceutical company, CureVac NV seeks to revolutionize the field of medicine through the use of mRNA to provide innovative treatment options for patients worldwide.
CureVac NV is primarily active in the biotechnology industry.
CureVac NV is a biopharmaceutical company specializing in developing messenger RNA (mRNA) therapeutics and vaccines. Founded in 2000, CureVac has a rich history of groundbreaking mRNA research. The company is headquartered in Tübingen, Germany, and has expanded its presence globally, including the establishment of CureVac Inc. in the United States. CureVac has pioneered the use of mRNA as a platform for various therapeutic applications, including cancer treatments, infectious diseases, and rare diseases. As a leading player in the field, CureVac has collaborated with numerous strategic partners and received significant funding for its innovative mRNA technology, demonstrating its promising potential in revolutionizing the medical industry.
CureVac NV, a renowned biopharmaceutical company, has attained several significant milestones in its journey. Notably, CureVac NV successfully completed its initial public offering (IPO) in August 2020, raising substantial capital for its research and development activities. Moreover, the company has made noteworthy advancements in the development of mRNA-based vaccines and therapeutics, showcasing promising results in preclinical and clinical trials. CureVac NV has also established strategic partnerships with various leading pharmaceutical companies, such as Bayer, GSK, and the Bill & Melinda Gates Foundation, further strengthening its research and commercialization capabilities. With its pioneering approach and collaborative efforts, CureVac NV continues to revolutionize the field of mRNA-based healthcare solutions.
CureVac NV is primarily present in various countries and regions. The company's presence spans across Europe, including Germany, Switzerland, and Austria, where its headquarters and research facilities are located. CureVac NV also has a strong presence in the United States, with operations in Cambridge, Massachusetts. The company's global expansion efforts have led to its presence in other regions, such as Latin America, Africa, and Asia, as it collaborates with partners and conducts clinical trials worldwide. With its widespread presence and international collaborations, CureVac NV is dedicated to advancing mRNA-based technologies and developing innovative solutions on a global scale.
CureVac NV represents a commitment to transforming the lives of patients through groundbreaking mRNA technology. With a strong corporate philosophy centered on innovation, quality, and collaboration, the company strives to develop and deliver mRNA-based therapeutics and vaccines to address a wide range of diseases, including cancer and infectious diseases. CureVac NV's values are built upon scientific excellence, patient-centricity, and sustainability. By harnessing the power of mRNA, the company aims to revolutionize healthcare and improve global health outcomes. Through continuous research and strategic partnerships, CureVac NV demonstrates its dedication to advancing the field of mRNA-based medicine and making a positive impact on society.
Analyytikot asettavat tällä hetkellä CureVac-osakkeelle keskimääräisen tavoitehinnan 4,99 EUR (mediaani: 4,99 EUR), mikä merkitsee +22,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.
11 analyytikkoa arvioi tällä hetkellä CureVac-osaketta: 6 suosittaa ostoa, 5 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat CureVac-yhtiöltä 88,19 M EUR liikevaihtoa ja −0,50 EUR osakekohtaista tulosta.
CureVac-osake (CVAC) on listattuna 10 pörssissä, muun muassa: NASDAQ (CVAC), London (0A9E.L), SIX (Zürich) (5CV.SW), XETRA (5CV.DE), Frankfurt (5CV.F), München (5CV.MU), Düsseldorf (5CV.DU), Hamburg (5CV.HM).
CureVac NV is a biotechnology company based in Tübingen, specializing in the development of mRNA-based therapies and vaccines. The company's business model is based on basic research and the development of innovative technologies for the production of mRNA-based products. One of CureVac's key areas is the development of mRNA vaccines. The company uses its platform technology to produce mRNA molecules that stimulate the body's immune system and induce a protective immune response. CureVac has already developed several vaccine candidates for diseases such as COVID-19 and cancer, which are currently in clinical development. Another focus of the company is the development of mRNA therapies. This involves using mRNA technology to produce therapeutic proteins or antibodies in the body to treat diseases. CureVac's therapy areas include cancer, rare diseases, and infectious diseases. To develop and manufacture these technologies, CureVac has its own research and development as well as production facilities. The company utilizes mRNA technology to produce clinical and commercial quantities of mRNA products. CureVac follows a highly automated and standardized production process to ensure high quality and large quantities of products. Collaboration with industry and scientific partners is also an important part of CureVac's business model. The company has formed partnerships with various pharmaceutical companies to jointly work on the development of mRNA-based therapies and vaccines. Additionally, CureVac works closely with universities and research institutions to advance basic research on mRNA technology. To expand the applications of its technology, CureVac continuously invests in researching new mRNA platforms and developing new technologies to improve the delivery of mRNA products in the body. This will allow for effective treatment of a wider range of diseases. In summary, CureVac's business model is based on the development and application of mRNA technology for the production of therapeutic proteins, antibodies, and vaccines. The company engages in both research and development activities and operates its own production facility, while collaborating with industry and scientific partners. With the use of its platform technology and continuous innovation, CureVac aims to effectively treat a wider range of diseases.
odotettu liikevaihto CureVac on 88,19 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto CureVac on −111,86 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
CureVac:n hinta-voitto-suhde (P/E) on tällä hetkellä −8,17. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan CureVac-osakkeen arvostusta.
CureVac:n hinta-myynti-suhde (P/S) on tällä hetkellä 10,37. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii CureVac-osakkeen arvostuskennuslukuna.
CureVac:n Eulpool-laatuscore on 7/10.
CureVac:n ISIN on NL0015436031. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
CureVac:n WKN on A2P71U. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
CureVac:n ticker on CVAC. Tämä pörssinoteeraus käytetään CureVac-osakkeiden kauppaan pörssissä.
CureVac osake
CureVac vertaisryhmä
CureVac Ticker
CureVac FIGI
Kaikki tunnusluvut ja syvällinen analyysi CureVac:sta
Meidän osakeanalyysimme CureVac-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut CureVac:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: